VEGF165, Bcl-2, p53, COX-2 and HER-family expression in patients with stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) and correlation with clinical outcome.

被引：0
|
作者：
Timotheadou, E
Murray, S
Linardou, H
Vrettou, AV
Skrickova, J
Kosmidis, P
Skarlos, DV
Pectasides, D
Fountzilas, G
机构：
[1] Papageorgiou Hosp, Dept Med Oncol, Thessaloniki, Greece
[2] Mol Biol & Genet Metropolitan Hosp, Athens, Greece
[3] Metropolitan Hosp, Dept Oncol, Athens, Greece
[4] Univ Hosp Brno, Brno, Czech Republic
[5] HYGEIA Hosp, Oncol Pathol Clin 2, Athens, Greece
[6] Errikos Dunant Hosp, B Oncol Dept, Athens, Greece
[7] Univ Athens, Attikon Hosp, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：681S / 681S
页数：1
相关论文
共 50 条
  • [21] Non-small cell lung carcinoma: Cyclin D1, bcl-2, p53, Ki-67 and HER-2 proteins expression in resected tumors
    Padovic, Svjetlana
    Babic, Mirsad
    Doric, Mirsad
    Hukic, Ajna
    Kuskunovic, Suda
    Hadzismajlovic, Ademir
    Serdarevic, Fadila
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2007, 7 (03) : 205 - 211
  • [22] Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines
    Loprevite, M
    Varesco, L
    Favoni, R
    Ferrara, GB
    Moro, F
    Ottaggio, L
    Fronza, G
    Campomenosi, P
    Abbondandolo, A
    Cutrona, G
    Roncella, S
    Albini, A
    Aluigi, MG
    Pozzi, S
    Pera, C
    Biticchi, R
    Gismondi, V
    Grossi, F
    Pennucci, MC
    Ardizzoni, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1997, 11 (06) : 1203 - 1208
  • [23] Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers
    Kitagawa, Y
    Wong, F
    Lo, P
    Elliott, M
    Verburgt, LM
    Hogg, JC
    Daya, M
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1996, 15 (01) : 45 - 54
  • [24] HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer
    Brattström, D
    Wester, K
    Bergqvist, M
    Hesselius, P
    Malmström, PU
    Nordgren, H
    Wagenius, G
    Brodin, O
    ACTA ONCOLOGICA, 2004, 43 (01) : 80 - 86
  • [25] Erratum to: EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features
    Feng Li
    Yongmei Liu
    Huijiao Chen
    Dianying Liao
    Yali Shen
    Feng Xu
    Jin Wang
    Journal of Experimental & Clinical Cancer Research, 30
  • [26] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    De Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [27] Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC) from ADAURA
    John, T.
    Grohe, C.
    Goldman, J.
    De Marinis, F.
    Kato, T.
    Wang, Q.
    Choi, J-H.
    Melotti, B.
    Fidler, M.
    Sainsbury, L.
    Stachowiak, M.
    Taggart, S.
    Wu, Y-L.
    Tsuboi, M.
    Herbst, R. S.
    Tarruella, M. Majem
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1548
  • [28] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
  • [29] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [30] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
12345